changes made to the company /restructure are lifetime and has reduced the cost of revenue , it will end up having the same revenue as metrics with much less cost .Compare this to a company like Neuren that has 4 times the market cap with less than %20 of Mayne Revenue and that will tell you what restructure /cost reduction program can achieve for mayne pharma
Nexstllis growth 267% units sold 256330 units sold, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.25 |
Change
-0.150(2.78%) |
Mkt cap ! $426.5M | |||
| Open | High | Low | Value | Volume |
| $5.35 | $5.41 | $5.19 | $1.239M | 231.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $5.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.36 | 1000 | 1 |
View Market Depth
| Last trade - 16.11pm 25/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |